Rabeprazole Sodium Delayed Release Tablets
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Amendment 0006 supercedes Amendment 0005 SPE2D2-20-R-0061 Rabeprazole Sodium DR Tablets is to allow only DIBBS submittial of offers. Any other submittial of offers is not acceptable. Closing date has been extended until April 23, 2020 at 3:00 PM DST.
Amendment 0005 SPE2D2-20-R-0061 Rabeprazole Sodium DR Tablets extends the closing date until April 23, 2020 at 3:00 PM DST and to update email submissions of offers.
Amendment 0004 SPE2D2-20-R-0061 Rabeprazole Sodium DR Tablets closing date extended until April 16, 2020 at 3:00 PM DST to allow email submissions of offers.
Amendment 0003 SPE2D2-20-R-0061 Rabeprazole Sodium DR Tablets closing date extended until April 09, 2020 at 3:00 PM DST.
Amendment 0002 SPE2D2-20-R-0061 Rabeprazole Sodium DR Tablets to incoproate three (3) DFARS clauses into solicitation.
Amendment 0001 SPE2D2-20-R-0061 Rabeprazole Sodium DR Tablets to incorporate two (2) DFARS clauses into solicitation.
Solicitation for Rabeprazole Sodium DR Tablets SPE2D2-20-R-0061.